RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Samsung Biologics Co Stock

Samsung Biologics Co P/E 2024

Samsung Biologics Co P/E

51.43

Ticker

207940.KS

ISIN

KR7207940008

WKN

A2AUB1

As of Dec 22, 2024, Samsung Biologics Co's P/E ratio was 51.43, a -21.35% change from the 65.39 P/E ratio recorded in the previous year.

The Samsung Biologics Co P/E history

Samsung Biologics Co Aktienanalyse

What does Samsung Biologics Co do?

Samsung Biologics Co Ltd is a biotechnology company based in South Korea. The company was founded in 2011 by Samsung Group and has since become one of the world's leading providers of biopharmaceutical manufacturing services. Samsung Biologics aims to improve the conduct of clinical studies by providing top-quality biopharmaceutical products and services. The business model of Samsung Biologics is to manufacture biopharmaceuticals for internationally leading pharmaceutical and biotechnology companies. The company offers a wide range of services, including cell line development, process development, and production processes. Samsung Biologics Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Samsung Biologics Co's P/E Ratio

The Price to Earnings (P/E) Ratio of Samsung Biologics Co is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Samsung Biologics Co's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Samsung Biologics Co is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Samsung Biologics Co’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Samsung Biologics Co stock

What is the price-to-earnings ratio of Samsung Biologics Co?

The price-earnings ratio of Samsung Biologics Co is currently 51.43.

How has the price-earnings ratio of Samsung Biologics Co changed compared to last year?

The price-to-earnings ratio of Samsung Biologics Co has increased by -21.35% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Samsung Biologics Co high compared to other companies?

Yes, the price-to-earnings ratio of Samsung Biologics Co is high compared to other companies.

How does an increase in the price-earnings ratio of Samsung Biologics Co affect the company?

An increase in the price-earnings ratio of Samsung Biologics Co would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Samsung Biologics Co affect the company?

A decrease in the price-earnings ratio of Samsung Biologics Co would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Samsung Biologics Co?

Some factors that influence the price-earnings ratio of Samsung Biologics Co are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Samsung Biologics Co pay?

Over the past 12 months, Samsung Biologics Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Samsung Biologics Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of Samsung Biologics Co?

The current dividend yield of Samsung Biologics Co is .

When does Samsung Biologics Co pay dividends?

Samsung Biologics Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Samsung Biologics Co?

Samsung Biologics Co paid dividends every year for the past 0 years.

What is the dividend of Samsung Biologics Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is Samsung Biologics Co located?

Samsung Biologics Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Samsung Biologics Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Samsung Biologics Co from 12/22/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 12/22/2024.

When did Samsung Biologics Co pay the last dividend?

The last dividend was paid out on 12/22/2024.

What was the dividend of Samsung Biologics Co in the year 2023?

In the year 2023, Samsung Biologics Co distributed 0 KRW as dividends.

In which currency does Samsung Biologics Co pay out the dividend?

The dividends of Samsung Biologics Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Samsung Biologics Co

Our stock analysis for Samsung Biologics Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Samsung Biologics Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.